Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company...
Neuroscience
AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering
IRVINE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused...
AEON Biopharma, Inc. Announces Launch of Proposed Public Offering
IRVINE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical...
AI Wellness Launches “Ask My Avatar Challenge” at CES, Ushering in a Powerful New Way to Engage
Three Stations to Host Interactive Experiences from January 6–11 LAS VEGAS, Jan. 3, 2025 /PRNewswire/ -- Assisted Intelligence Wellness (known...
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total...
Firefly Neuroscience Closes on Financing of up to $12.4 Million
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence...
AI Wellness Launches Groundbreaking 2025 Initiatives to Celebrate Visionaries, Innovators, and Clinics
LAS VEGAS, Dec. 30, 2024 /PRNewswire/ -- Assisted Intelligence Wellness Inc. (AI Wellness), a global leader in integrating AI with personalized...
121 Local & Regional EHR Vendors Across 53 Countries to Know: Showcasing Global Health IT Achievements With Insights From Black Book Research
Black Book unveils critical insights into the global EHR landscape, spotlighting 121 local and regional vendors across 53 countries as...
Darmiyan Enters Medicare GUIDE Program Through Partnership with Five Star Home Health Care, CareBrains, and Brain Watch Coalition
SAN FRANCISCO, Dec. 19, 2024 /PRNewswire/ -- Darmiyan, Inc., a leader in brain health technology, proudly announces its participation in...
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company’s Pipeline Development
MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing...
Lexaria Forms New Scientific Advisory Board
North American drug delivery development experts added to help guide Lexaria's strategic plans KELOWNA, BC / ACCESSWIRE / December 18,...
Noema Pharma Appoints Volker Knappertz, M.D., as Executive Vice President of Research & Development
BASEL, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS)...
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical...
Exploring Space and Neurotherapeutics at the 2025 Ultrasound Event: A Journey into the Future of Medical Ultrasound
ORLANDO, Fla., Dec. 16, 2024 /PRNewswire/ -- The 2025 AIUM Annual Convention, hosted by the American Institute of Ultrasound in...
This Week in Health News: 15 Stories You Need to See
A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including a survey on nicotine use...
BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Reunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting
MORRISTOWN, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment...
MIRA Pharmaceuticals Validates Ketamir-2’s Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain MIAMI, FL / ACCESSWIRE /...
Cala® Health Closes Oversubscribed $50 Million Financing To Propel Growth
SAN MATEO, Calif., Dec. 9, 2024 /PRNewswire/ -- Cala Health, the non-invasive bioelectronic medicine leader, today announced it has completed...
Nature Methods Names Spatial Proteomics “Method of the Year 2024” — Akoya Biosciences Celebrates Industry Milestone
MARLBOROUGH, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced that...